Corbus pharmaceuticals holdings, inc. (CRBP)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue from awards

1,762

2,573

2,589

29,094

1,885

-

1,090

853

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue from awards

-

-

-

-

-

-

-

-

950

0

796

350

1,293

375

742

396

396

364

170

113

0

-

0

-

-

-

Operating expenses:
Research and development

23,947

23,487

22,152

22,181

21,783

15,780

12,807

10,259

9,765

8,286

5,622

5,763

6,366

5,380

4,315

3,567

2,173

1,823

1,634

1,707

723

571

452

169

61

28

General and administrative

7,699

6,276

5,534

5,207

6,624

3,737

3,181

2,987

3,050

2,575

2,130

1,878

2,380

2,567

1,760

1,021

1,109

1,041

790

969

811

687

365

294

43

16

Total operating expenses

31,647

29,763

27,686

27,389

28,408

19,518

15,988

13,247

12,815

10,861

7,753

7,641

8,746

7,948

6,076

4,588

3,283

2,865

2,425

2,676

1,535

1,259

818

464

105

45

Operating loss

-29,885

-27,190

-25,096

1,705

-26,522

-17,590

-14,897

-12,393

-11,864

-10,861

-6,956

-7,291

-7,452

-7,572

-5,333

-4,191

-2,887

-2,500

-2,254

-2,562

-1,535

-1,259

-818

-464

-105

-45

Other income (expense):
Other income

-

-

4,109

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income, net

-

-

292

448

-

-

268

266

203

133

43

5

1

0

1

4

-5

-

1

0

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

11

11

9

Interest income, net

101

-

-

-

334

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

Forgiveness of interest on note payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

-

-

-

Gain on the settlement of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

145

-

-

-

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

29

-1

-

Foreign currency exchange gain (loss), net

126

-14

-96

-1

-46

40

28

58

-33

35

-52

-10

-14

2

-14

-1

0

-

0

0

-

-0

5

0

-0

-4

Other income, net

228

609

4,305

447

287

284

296

324

169

168

-8

-5

-12

2

-12

2

-5

2

1

0

-0

-1

158

-40

-10

-14

Net loss

-29,656

-26,580

-20,790

2,152

-26,234

-17,306

-14,601

-12,069

-11,695

-10,693

-6,965

-7,296

-7,465

-7,570

-5,346

-4,189

-2,892

-2,498

-2,253

-2,562

-1,535

-1,260

-659

-504

-115

-59

Net income (loss) per share, basic

-

-

-

0.03

-

-

-

-0.21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per share, diluted

-

-

-

0.03

-

-

-

-0.21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding, basic

-

-

-

64,546

-

-

-

57,157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of common shares outstanding, diluted

-

-

-

68,511

-

-

-

57,157

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basic and diluted

-0.43

-

-0.32

-

-0.43

-

-0.26

-

-0.21

-0.20

-0.14

-0.15

-0.16

-0.17

-0.12

-0.11

-0.08

-0.06

-0.06

-0.10

-0.06

-0.06

-0.03

-0.02

-0.02

-0.01

Weighted average number of common shares outstanding, basic and diluted

69,272

-

64,660

-

61,675

-

57,218

-

56,367

53,828

50,221

50,193

46,381

44,348

43,783

38,748

37,605

37,857

34,770

26,901

25,871

26,060

25,542

22,071

6,964

6,964